Business Description
BioVaxys Technology Corp
NAICS : 541714
SIC : 3741
ISIN : CA09076M1014
Share Class Description:
XCNQ:BIOV: Ordinary SharesDescription
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.06 | |||||
| Equity-to-Asset | -0.1 | |||||
| Debt-to-Equity | -0.33 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -7.2 | |||||
| 3-Year EPS without NRI Growth Rate | -7.9 | |||||
| 3-Year FCF Growth Rate | 42.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.23 | |||||
| 9-Day RSI | 56.69 | |||||
| 14-Day RSI | 53.42 | |||||
| 6-1 Month Momentum % | -7.14 | |||||
| 12-1 Month Momentum % | 116.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.39 | |||||
| Quick Ratio | 0.39 | |||||
| Cash Ratio | 0.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -25.1 | |||||
| Shareholder Yield % | -14.17 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -6.08 | |||||
| EV-to-EBITDA | -6.08 | |||||
| EV-to-FCF | -19.58 | |||||
| Earnings Yield (Greenblatt) % | -16.45 | |||||
| FCF Yield % | -4.98 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioVaxys Technology Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.029 | ||
| Beta | 1.59 | ||
| Volatility % | 179.59 | ||
| 14-Day RSI | 53.42 | ||
| 14-Day ATR (C$) | 0.005996 | ||
| 20-Day SMA (C$) | 0.06125 | ||
| 12-1 Month Momentum % | 116.67 | ||
| 52-Week Range (C$) | 0.03 - 0.1 | ||
| Shares Outstanding (Mil) | 262.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioVaxys Technology Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioVaxys Technology Corp Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
BioVaxys Technology Corp Frequently Asked Questions
What is BioVaxys Technology Corp(XCNQ:BIOV)'s stock price today?
The current price of XCNQ:BIOV is C$0.07. The 52 week high of XCNQ:BIOV is C$0.10 and 52 week low is C$0.03.
When is next earnings date of BioVaxys Technology Corp(XCNQ:BIOV)?
The next earnings date of BioVaxys Technology Corp(XCNQ:BIOV) is .
Does BioVaxys Technology Corp(XCNQ:BIOV) pay dividends? If so, how much?
BioVaxys Technology Corp(XCNQ:BIOV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers